Anabolizing and anti-pain effect of the short-term treatment with medroxyprogesterone acetate (MAP) at high oral doses in oncology.
D005260:Female; D006801:Humans; D008297:Male; D008525:Medroxyprogesterone / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D009369:Neoplasms / Q000188:drug therapy*
D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone